Clinical Trials Logo
  1. Home
  2. Prostate Cancer
  3. NCT00050297
  4. Details
NCT00050297 Clinical Trial

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

Prostate Cancer Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00050297
Other study ID # 598-CL-004
Secondary ID
Status Terminated
Phase Phase 2
First received December 3, 2002
Last updated June 6, 2012
Est. completion date February 2004

Study information
Verified date June 2012
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Recruitment information / eligibility
Status Terminated
Enrollment 0
Est. completion date February 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• YM598

Locations
Country Name City State
Belgium University Clinic AZ Brussels
Belgium University Clinic UCL St. Luc Brussels
Czech Republic Private Urology Out-patient Ward Jablonec nad Nisou
Czech Republic Clinic of Urology, University Hospital Králové
Czech Republic Clinic of Urology, University Hospital Olomouc
Czech Republic Clinic of Urology, University Hospital Prague
France Hôpital Bichat, service de Urology Paris
Germany Haingasse 22 Bad Homburg
Germany Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus Dresden
Germany Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße Marburg
Germany Krummbogen 15 Marburg
Poland Regional Hospital, Department of Urology Bydgoszcz
Poland MedSource Poland Gdansk
Poland Bielanski Hospital, Department of Urology Warszawa
Poland Oncology Center, Department of Urinary Tract Cancer Warszawa
Poland Medical University, Clinic of Urology Wroclaw
Spain Complejo Hospitaliaro Juan Canalejo, Servicio de Urología Corunna
Spain Fundacion Hospital Alcorcón, Servicio Urología Madrid
Spain Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra. Madrid
United Kingdom Department of Urology, Bristol Royal Infirmary Bristol
United Kingdom Department of Urology, Gartnavel Hospital Glasgow
United Kingdom Department of Urology, Norfolk & Norwich Hospital Norwich
United Kingdom Department of Urology, Taunton & Somerset Hospital Taunton

Sponsors (2)
Lead Sponsor Collaborator
Astellas Pharma Inc Astellas Pharma US, Inc.

Countries where clinical trial is conducted

Belgium,  Czech Republic,  France,  Germany,  Poland,  Spain,  United Kingdom, 

See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A